Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin-like 1 (CLECL1) encodes a type II transmembrane protein of the C-type lectin-like family, highly expressed on dendritic and B cells[1]. It is presumed to function as a T cell costimulatory molecule promoting interleukin-4 production and possibly participates in immune response regulation[1]. However, biological details remain limited, and there is significant ambiguity in the literature; in some contexts, CLECL1 may be referenced as a pseudogene[1][3]. CLECL1 is not a validated therapeutic target, and its precise signaling properties, endogenous ligands, or clinical disease roles remain poorly characterized[3]. The broader C-type lectin-like family encompasses receptors involved in immune recognition, cell adhesion, and immunoregulation, but specifically, CLECL1’s function, mechanism, and therapeutic relevance have not been clearly defined[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-type lectin-like 1 (CLECL1).